Full-Time

Director – Oxford Research Technology

Posted on 7/22/2026

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

No salary listed

Oxford, UK

Hybrid

Hybrid role; up to two days remote per week.

Bachelor's

Category
Engineering Management (1)
Required Skills
Forecasting

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • Bachelor's degree in technology discipline or equivalent
  • Relevant experience, or an equivalent combination of education and experience.
  • Demonstrated leadership managing enterprise-scale technology platforms and support organizations.
  • Experience leading complex programs, portfolios, and vendor ecosystems with financial accountability.
  • Experience operating as a product owner, business relationship manager, or similar demand-shaping role — translating ambiguous stakeholder input into structured, prioritized backlog items.
  • Strong senior-level business engagement and stakeholder partnership capabilities.
  • Deep understanding of enterprise technology operations, cyber security, ITSM, and system lifecycle practices.
  • Proven people leadership experience building and sustaining high-performing teams.
  • Program, portfolio, demand, and financial management expertise.
  • Excellent analytical, problem-solving, communication, and executive-level presentation skills.
  • Ability to balance operational stability with innovation in regulated environments.
  • Comfort operating in a matrixed accountability model — shaping and routing demand where the build/architecture decision rests with a peer platform owner, not this role.
Responsibilities
  • Build and sustain strong, trust-based relationships with senior business, quality, and DTE leaders, acting as a strategic partner with sustained impact on enterprise laboratory goals.
  • Lead, develop, and retain a highly effective Lab Engineering Support organization, leveraging internal resources and external partners through a managed service provider model.
  • Ensure stable, secure, and compliant laboratory technology operations across both IT and OT environments, aligned to cyber security, ITSM, ITIL, and DTE system lifecycle standards.
  • Serve as the primary point of accountability for laboratory technology partnering with DTE Compliance, Cyber Security, Internal Audit, and Quality Assurance.
  • Own and manage the site's operating budget, ensuring disciplined financial planning, forecasting, vendor management, and value realization across services and platforms.
  • Oversee a portfolio of programs, projects, platform releases, and enhancements delivered at the site, ensuring quality, timeliness, and alignment with business outcomes.
  • Attract, develop, and retain top talent; carry full people-management accountability for assigned staff.
  • Serve as the single accountable owner for technology adoption, change, and the DTE relationship at Oxford — the primary partner to the site SVP and research leadership.
  • Act as the site's product owner: capture requirements and user stories directly from scientists and shape raw, ambiguous input into clear, prioritized demand.
  • Be the single front door for Oxford — route shaped requirements to the correct platform owner (within Laboratory Solutions or peer DTE platform organizations) rather than site stakeholders engaging each platform team directly.
  • Drive local adoption and change management for new platform capabilities; carry roadmap and delivery updates back to site scientists and leadership on a regular cadence.
  • Represent the site's voice in cross-site, cross-functional prioritization forums, ensuring the shared platform roadmap reflects the site's highest-value needs.
  • Maintain a transparent, current view of the site's demand status and backlog position that site stakeholders can see and understand.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Vertex raised 2026 revenue guidance to $13.1-$13.2 billion after Q2 growth.
  • Povetacicept has a November 30, 2026 PDUFA date, opening nephrology revenue.
  • JOURNAVX hit $50 million in Q2 2026, while CASGEVY grew 151% year over year.

What critics are saying

  • Sionna axed SION-719 on August 10, 2026, but CF competition keeps advancing.
  • Zimislecel faced a voluntary manufacturing pause in 2026, exposing cell-therapy execution risk.
  • Crinetics adds $8.8 billion integration risk; a failed close leaves Vertex overdependent on CF.

What makes Vertex Pharmaceuticals unique

  • Vertex still owns CFTR modulators; Q2 2026 CF revenue reached $3.2 billion.
  • Vertex broadened beyond CF with CASGEVY, JOURNAVX, and Crinetics, announced July 2026.
  • Vertex moves fast: CASGEVY pediatric FDA approval arrived 53 days after filing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.

Yahoo Finance
Aug 12th, 2026
Vertex Pharmaceuticals beats Q2 revenue estimates with $3.33B, driven by CF portfolio and newer products

Vertex Pharmaceuticals reported strong second-quarter results, with revenue of $3.33 billion beating analyst estimates of $3.19 billion. The company attributed growth to its cystic fibrosis portfolio and newer products like CASGEVY and JOURNAVX. CEO Reshma Kewalramani highlighted that ALYFTREK and TRIKAFTA continued to drive CF revenue, whilst European launches benefitted from fewer monitoring requirements. The company raised its full-year revenue guidance to $13.15 billion at the midpoint from $13.03 billion. Adjusted earnings per share came in at $4.73, in line with analyst expectations of $4.75. Adjusted operating income reached $1.42 billion, exceeding estimates of $1.37 billion with a 42.7% margin. During the earnings call, analysts questioned management about Phase II/III study doses, payer dynamics for JOURNAVX, and clinical outcomes for next-generation CF therapies.

Yahoo Finance
Aug 11th, 2026
Vertex Q2 2026 revenue up 12% year-on-year, announces Crinetics acquisition

Vertex Pharmaceuticals reported strong second quarter 2026 results during its earnings call on 3 August. The company's total revenue grew 12% year-on-year, driven by its cystic fibrosis portfolio and newer products CASGEVY and JOURNAVX. CEO Dr Reshma Kewalramani highlighted excellent performance across the company's commercial portfolio and research pipeline. Vertex also announced a definitive agreement to acquire Crinetics Pharmaceuticals, which will add rare endocrine diseases as a fifth therapeutic area alongside cystic fibrosis, sickle cell disease, beta-thalassemia, and pain management. The company emphasised 2026 as a year focused on execution across commercial, clinical, and regulatory fronts, with significant progress made during the quarter.

Yahoo Finance
Aug 7th, 2026
Sionna Therapeutics challenges Vertex Pharmaceuticals' $12B cystic fibrosis market dominance

Sionna Therapeutics is challenging Vertex Pharmaceuticals' dominance in the cystic fibrosis (CF) drug market. Vertex, valued at nearly $123 billion, generated $3.2 billion in CF-related sales in Q2, representing most of its $3.33 billion total revenue. Sionna, worth $2.2 billion, claims its approach could restore normal function to the CFTR protein, which causes CF when misfolded. Vertex's current treatments improve the protein's shape and function but don't restore normal function for most patients. Vertex generates over $12 billion annually from CF treatments. However, several companies, including AbbVie, have previously attempted to challenge Vertex's market position without success. Vertex has maintained its position since receiving its first CF drug approval in 2012.

INACTIVE